PLOS: DNA Science

OCTOBER 3, 2024

One of the oldest and most successful immunotherapies is simpler: a tamed version of a classic vaccine, against the infectious disease tuberculosis (TB). “BCG” is the “treatment” vaccine’s technical name, for Mycobacterium bovis Bacillus Calmette-Guérin. The approach worked.

Vaccine 52

Vaccine Immune Response DNA Doctors 52

Drug Target Review

JANUARY 23, 2024

What innovative approaches and technologies are anticipated to reshape immuno-oncology treatments in 2024? Immuno-oncology, notably through checkpoint inhibitors, has significantly reshaped cancer treatment over the past decade.

Treatment 122

Treatment Immune Response Vaccine Therapies 122

Drug Discovery World

JANUARY 22, 2024

For the patient as well as for doctors, this means creating more time to make decisions, as the company believes: “Patients – and their quality of life – shouldn’t have to wait for a broken system to provide an answer six months too late.

Vaccine 147

Vaccine Immune Response Engineering Virus 147

Drug Target Review

MARCH 26, 2024

DGG: At Osivax, we’re working on a new class of vaccines that target invariant parts of mutating viruses; this approach is disruptive and very different from conventional vaccines. DGG: Vaccines are experiencing a revolution in the post-COVID era with the emergence of mRNA technology.

Vaccine 110

Vaccine Virus Immune Response Science 110

NIH Director's Blog: Drug Development

DECEMBER 15, 2020

Indeed, it shows that no matter your current experience with COVID-19, there are opportunities to get involved to develop vaccines and medicines that will help everyone. This registry is creating a list of potential volunteers willing to take part in ongoing or future NIH clinical trials focused on preventing COVID-19—like vaccines.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Broad Institute

DECEMBER 6, 2023

Using single-cell RNA sequencing to analyze gene expression in individual cells, the researchers have found how 86 major cytokines affect 17 immune cell types in mice. NH: This is the first single-cell resolution dictionary of each major immune cell type responding to each major cytokine in vivo at an unprecedented scale.

Immune Response 138

Immune Response RNA Medical Schools Disease 138

The Pharma Data

MARCH 16, 2021

Durability: 1,2 Robust joint and skin response rates and mean improvements from baseline in outcome measures were maintained through two years, and approximately 90 percent of patients randomized to TREMFYA q4w or q8w continued treatment with TREMFYA through Week 100. TREMFYA was approved in the U.S. TREMFYA is approved in the U.S.,

Treatment 52

Treatment Pharmacokinetics Disease Pharmaceutical Companies 52